Eton Pharmaceuticals, Inc. (ETON)

NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-23

$50.00-0.04%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Eton Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	45.86M
EPS	—	0.366
FY 2026 · Annual
Revenue	Over $145M	149.71M
EPS	—	1.087
Gross margin	Over 70%non-GAAP	—
FY 2027 · Annual
Revenue	—	220.38M
EPS	—	2.085

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Report at least 30% adjusted EBITDA margin in 2026	Management targets a gross margin over 70% and adjusted EBITDA margin above 30%.	Improving	adjusted EBITDA margin falls below 20% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA margin increased from 24% in 2026-Q1 to 43% in 2026-Q2. Management raised full year 2026 Adjusted EBITDA margin guidance from at least 30% to at least 35%, indicating delivery and improving profitability. Delivery assessment Oct 24, 2026
Achieve adjusted gross margin over 70% in 2026	Management targets a gross margin over 70% and adjusted EBITDA margin above 30%.	Improving	gross margin falls below 60% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Adjusted gross margin was 67% in 2026-Q1 and improved to 73% in 2026-Q2. Management expects full year 2026 adjusted gross margin to exceed 70%, inclusive of milestone expenses, showing progress and delivery on margin targets. Delivery assessment Oct 24, 2026
Expand product portfolio through acquisitions	The company is expanding its product portfolio with new drug acquisitions like IMPAVIDO and HEMANGEOL.	Intact	failure to complete or integrate acquisitions by end 2026	2 acquisitions completed (Jul & Oct 2026) vs target by end 2026 ETON finalized license agreements for LIBERVANT and ASN-001 in late 2026, confirming active portfolio expansion. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 disclosures including 2026-Q2 and 2026-10-14. Management completed acquisitions of ASN-001 and IMPAVIDO and licensed LIBERVANT for U.S. commercialization, expanding the product portfolio. These actions demonstrate active execution on portfolio growth strategy. Delivery assessment Oct 24, 2026
Increase 2026 revenue to exceed $120 million	A primary condition in Eton Pharmaceuticals, Inc.'s published investment case. The stated target is >= $120 million.	Intact	revenue falls below $110 million in FY26	Revenue: $37.589M FY2026-Q2; GAAP. Published target: >= $120 million. Target period is not explicitly aligned with this observation. Source published Aug 13, 202637,589,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e9172e2b-e142-4ab6-9527-4d2ecdce3513. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $24.3 million in 2026-Q1 to $37.6 million in 2026-Q2, a 99% year-over-year increase. Management raised full year 2026 revenue guidance from over $120 million to at least $145 million, indicating delivery and upward trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 3
2026-07-27	Unavailable	Unavailable	2 / 3
2026-07-28	Unavailable	Unavailable	2 / 4
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	Unavailable	2 / 3
2026-07-31	Unavailable	Unavailable	2 / 4
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	Unavailable	2 / 4
2026-08-03	Unavailable	Unavailable	2 / 4
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	Unavailable	2 / 4
2026-08-06	Unavailable	Unavailable	2 / 3
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	Unavailable	2 / 4
2026-08-10	Unavailable	Unavailable	2 / 3
2026-08-11	Unavailable	Unavailable	2 / 4
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	4	0	0
2026-08-01	4	0	0
2026-09-01	4	0	0
2026-10-01	4	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Craig-HallumOct 15 · prior Jul 28

$62.00 → $78.00+25.8%

$0$42.90$85.80

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Report at least 30% adjusted EBITDA margin in 2026Direct metric needs a verified mapping
Achieve adjusted gross margin over 70% in 2026Direct metric needs a verified mapping
Increase 2026 revenue to exceed $120 millionRevenue: $37.589M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-25.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Eton Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ETON is a high-risk growth story with recent strong financial performance, rather than an established profitable compounder. The long-term thesis is intact, supported by rapid revenue growth and higher guidance, though earnings quality remains weak because the company is loss-making.

What's priced into Eton Pharmaceuticals, Inc.

ETON is valued at a premium to peers, with the snapshot describing its valuation as expensive. The priced-in assessment is marked justified, with no fragility warning, but the model has low confidence and points to optionality, or value tied to possible future opportunities, as a source of valuation support.

What the fundamentals likely do

Near term, management’s 2026 revenue and adjusted EBITDA margin goals appear on track: second-quarter revenue rose 99% year over year, and guidance was raised. Adjusted gross margin improved to 73% in the second quarter, though progress toward the full-year goal is described as mixed; losses, erratic earnings surprises, and the risk of a guidance cut remain concerns.

What Eton Pharmaceuticals, Inc. hinges on

Over the next few quarters, the thesis depends on management delivering at least $145 million in 2026 revenue and at least a 35% adjusted EBITDA margin, while sustaining gross margin above 70%. A guidance cut would be a meaningful setback; continued strength from healthcare sector peers could support the sector backdrop, while weaker job growth and rising recession fears could weigh on cyclical healthcare names.